Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vismodegib

FDA-approved product (capsule, oral), marketed as Erivedge.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Vismodegib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Basal cell carcinoma
  • Cancer
  • Neoplasm
  • Skin basal cell carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hedgehog pathway inhibitors
FDA pharmacologic class
Hedgehog Pathway Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vismodegib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vismodegib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Molecularly Tailored Therapy in Advanced Pancreatic Cancer

    NCT07802418 · start 2026-10

    Registered record
    Registry ID
    NCT07802418
    Conditions
    Pancreatic Cancer
    Interventions
    Arm 1: Molecularly Tailored Therapy; Arms 2: Standard-of-Care Therapy; Arm 3: Standard-of-Care Observational Cohort
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2032-06
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionArm 1: Molecularly Tailored Therapy; Arms 2: Standard-of-Care Therapy; Arm 3: Standard-of-Care Observational Cohort
    PhasePhase 2
    Registry statusNot yet recruiting

  • Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

    NCT06616623 · start 2024-12-31

    Registered record
    Registry ID
    NCT06616623
    Conditions
    Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
    Interventions
    Atezolizumab; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Suspended
    Start
    2024-12-31
    Completion
    2027-12-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
    InterventionAtezolizumab; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging +1 more
    PhasePhase 1
    Registry statusSuspended

  • To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

    NCT06344052 · start 2024-04-09

    Registered record
    Registry ID
    NCT06344052
    Conditions
    Basal Cell Carcinoma
    Interventions
    SP-002; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-04-09
    Completion
    2029-03-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBasal Cell Carcinoma
    InterventionSP-002; Vismodegib
    PhasePhase 2
    Registry statusRecruiting

  • Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

    NCT05538091 · start 2023-05-15

    Registered record
    Registry ID
    NCT05538091
    Conditions
    Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; PARP Inhibitor; Hedgehog Inhibitor
    Interventions
    Vismodegib; Atezolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-05-15
    Completion
    2032-09-30
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlatinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; PARP Inhibitor; Hedgehog Inhibitor
    InterventionVismodegib; Atezolizumab
    PhasePhase 2
    Registry statusRecruiting

  • Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

    NCT05651828 · start 2023-03-23

    Registered record
    Registry ID
    NCT05651828
    Conditions
    Advanced Basal Cell Carcinoma
    Interventions
    Vismodegib 150 MG Oral Capsule
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2023-03-23
    Completion
    2029-12
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Basal Cell Carcinoma
    InterventionVismodegib 150 MG Oral Capsule
    PhaseEarly phase 1
    Registry statusRecruiting

  • The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

    NCT05159245 · start 2021-12-10

    Registered record
    Registry ID
    NCT05159245
    Conditions
    Advanced Cancer; Solid Tumor; Haematological Malignancy
    Interventions
    Alectinib; Cobimetinib; Vismodegib; Trastuzumab+Pertuzumab; Entrectinib; Atezolizumab; Vemurafenib; Regorafenib; Apalutamide; Abemaciclib; Tepotinib; Dabrafenib; Trametinib; Dabrafenib+Trametinib; Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-12-10
    Completion
    2026-11-25
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer; Solid Tumor; Haematological Malignancy
    InterventionAlectinib; Cobimetinib; Vismodegib; Trastuzumab+Pertuzumab +11 more
    PhasePhase 2
    Registry statusRecruiting

  • Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study

    NCT05463757 · start 2021-11-01

    Registered record
    Registry ID
    NCT05463757
    Conditions
    Basal Cell Carcinoma; Locally Advanced Basal Cell Carcinoma; Metastatic Basal Cell Carcinoma; Gorlin Syndrome; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Carcinoma; Basal Cell Tumor; Skin Cancer; Neoplasm of Skin; Neoplasms, Basal Cell
    Interventions
    Vismodegib; Sonidegib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-11-01
    Completion
    2026-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBasal Cell Carcinoma; Locally Advanced Basal Cell Carcinoma; Metastatic Basal Cell Carcinoma; Gorlin Syndrome +7 more
    InterventionVismodegib; Sonidegib
    PhaseNot recorded
    Registry statusRecruiting

  • Improving Public Cancer Care by Implementing Precision Medicine in Norway

    NCT04817956 · start 2021-04-01

    Registered record
    Registry ID
    NCT04817956
    Conditions
    Cancer Metastatic
    Interventions
    Atezolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-04-01
    Completion
    2045-04-30
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer Metastatic
    InterventionAtezolizumab
    PhasePhase 2
    Registry statusRecruiting

  • The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

    NCT04591431 · start 2020-10-07

    Registered record
    Registry ID
    NCT04591431
    Conditions
    Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
    Interventions
    Erlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab; Lapatinib; Everolimus; Vemurafenib; Cobimetinib; Alectinib; Brigatinib; Palbociclib; Ponatinib; Vismogedib; Itacitinib; Ipatasertib; Entrectinib; Atezolizumab; Nivolumab; Ipilimumab; Pemigatinib; Oncology Drugs; Pralsetinib; Selpercatinib; Talazoparib; Tepotinib; Alpelisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-10-07
    Completion
    2025-06
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
    InterventionErlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab +22 more
    PhasePhase 2
    Registry statusUnknown

  • Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

    NCT04416516 · start 2020-07-16

    Registered record
    Registry ID
    NCT04416516
    Conditions
    Basal Cell Carcinoma; Basal Cell Nevus Syndrome
    Interventions
    ASN-002
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-07-16
    Completion
    2024-02-14
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBasal Cell Carcinoma; Basal Cell Nevus Syndrome
    InterventionASN-002
    PhasePhase 2
    Registry statusCompleted

  • Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

    NCT03297606 · start 2018-03-23

    Registered record
    Registry ID
    NCT03297606
    Conditions
    Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
    Interventions
    Olaparib; Dasatinib; Nivolumab plus Ipilimumab; Axitinib; Bosutinib; Crizotinib; Palbociclib; Sunitinib; Temsirolimus; Erlotinib; Trastuzumab plus Pertuzumab; Vemurafenib plus Cobimetinib; Vismodegib; Tucatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2018-03-23
    Completion
    2027-01-31
    Enrolment
    720

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
    InterventionOlaparib; Dasatinib; Nivolumab plus Ipilimumab; Axitinib +10 more
    PhasePhase 2
    Registry statusRecruiting

  • To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma

    NCT02956889 · start 2016-10

    Registered record
    Registry ID
    NCT02956889
    Conditions
    Carcinoma, Basal Cell
    Interventions
    Vismodegib; Radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-10
    Completion
    2020-01
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Basal Cell
    InterventionVismodegib; Radiotherapy
    PhasePhase 2
    Registry statusTerminated

  • Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

    NCT06357988 · start 2016-06-20

    Registered record
    Registry ID
    NCT06357988
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphatic System Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma
    Interventions
    Biopsy Procedure; Biospecimen Collection; Echocardiography Test; Radionuclide Imaging; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2016-06-20
    Completion
    2026-12-31
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphatic System Neoplasm; Refractory Lymphoma +2 more
    InterventionBiopsy Procedure; Biospecimen Collection; Echocardiography Test; Radionuclide Imaging +1 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer

    NCT02690948 · start 2016-02-01

    Registered record
    Registry ID
    NCT02690948
    Conditions
    Skin Basal Cell Carcinoma
    Interventions
    Pembrolizumab; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2016-02-01
    Completion
    2018-08-29
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Basal Cell Carcinoma
    InterventionPembrolizumab; Vismodegib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)

    NCT02593760 · start 2016-01-25

    Registered record
    Registry ID
    NCT02593760
    Conditions
    Myelofibrosis
    Interventions
    Placebo; Ruxolitinib; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-01-25
    Completion
    2017-07-12
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelofibrosis
    InterventionPlacebo; Ruxolitinib; Vismodegib
    PhasePhase 1
    Registry statusCompleted